Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center


VICC toll-free number 1-877-936-8422

Gautam Chaudhuri, Ph.D.


Contact Information:

Meharry Medical College
1005 Dr. D.B. Todd, Jr. Blvd.
Nashville, TN 37208

Research Specialty

Gene expression regulations in breast cancer cells and professional mononuclear phagocytes

Research Description

Dr. Chaudhuri's research interests include (a) the understanding the genetic and epigenetic regulations of BRCA2 gene expression with respect to the proliferation and metastasis of human breast cancer cells; (b) Evaluation of the roles of SNAI proteins in the regulation of calcitriol biosynthesis and function in human breast cancer cells; (c) Evaluation of the role of adiponectin gene expression in tumor-associated adipocytes by the SNAI proteins; (d) evaluation of the role of non-coding RNA biosynthesis in determining the immune functions of mononuclear phagocytes including monocytes, M1 and M2 macrophages, neutrophils and dendritic cells; and, (e) identification and validation of targets of nucleic acid- and peptide-based drugs against breast cancer and parasitic infections.

Current focus of his lab is on the following specific research topics:

(i) Protease activated receptor 1, mu-calpain and TFIIIC110-mediated modulation of macrophage immune functions by proteases such as MMP1 secreted by breast cancer cells, thrombin, and the surface protease gp63 of the parasitic protozoan Leishmania through the inhibition of the RNA polymerase III promoters that contain B-box element.

(ii) SNAI protein mediated repression of vitamin D metabolism and function in breast cancer cells and development of combinatorial drug regimen that include ds-DNA molecular decoy, siRNA, peptide aptamers and vitamin D3 to combat breast cancer progression and metastasis.

(iii) Biology of a novel transcriptional repressor protein ZAR2 which is transcribed from the reverse activity of the BRCA2 gene bidriectional promoter.

(iv) Redox regulation of BRCA2 gene expression through SNAI2 and peroxiredoxin 5 in human breast cancer cells.